EU negative opinion for BioPartners' Biferonex for MS
This article was originally published in Scrip
Executive Summary
BioPartners GmbH's Biferonex (interferon beta-1a) has received a negative opinion from the EU's CHMP, which said the company had failed to prove its efficacy for the treatment of relapsing-remitting multiple sclerosis. The company said that it plans to appeal the decision.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.